Yahoo Finance

Allyx Therapeutics Awarded $3.3 Million NIH Grant to Support Further Clinical Studies of Lead Candidate ALX-001

NEW HAVEN, Conn., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Allyx Therapeutics announced today that it has been awarded a $3.3 million grant from the National Institutes of Health as part of its Small ...
Yahoo Finance

Allyx Therapeutics Announces Expansion into Parkinson’s Disease Clinical Research with Lead Compound ALX-001 Following IND Acceptance

NEW HAVEN, Conn., March 05, 2024 (GLOBE NEWSWIRE) -- Allyx Therapeutics, a clinical-stage biotechnology company which is developing ALX-001, a highly selective, first-in-class, synapse-targeted, ...
Pharmabiz

Allyx Therapeutics reports first Alzheimer’s disease patient treated with its lead compound ALX-001

Allyx Therapeutics, a clinical-stage biotechnology company working to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases, announced that the ...
Hartford Business

New Haven-based Allyx Therapeutics awarded $3.3M NIH grant

The National Institutes of Health (NIH) on Tuesday awarded a $3.3 million grant to a New Haven-based biotechnology company to further study its oral therapy for treating Alzheimer’s and Parkinson’s ...
WFLA News Channel 8

Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults

NEW HAVEN, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allyx Therapeutics, a clinical-stage biotechnology company which is developing ALX-001, a highly selective, first-in-class, synapse-targeted, ...
Mena FN

Allyx Therapeutics Announces First Parkinson’S Disease Patient Treated With ALX-001

(MENAFN- GlobeNewsWire - Nasdaq) Allyx continues to advance clinical research of its first-in-class oral compound for neurodegenerative diseases NEW HAVEN, Conn., Sept. 04, 2024 (GLOBE NEWSWIRE) -- ...